financetom
Business
financetom
/
Business
/
Venture capital investors express worry about sluggish late-stage funding progress
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Venture capital investors express worry about sluggish late-stage funding progress
Nov 2, 2023 10:37 AM

In a world where the startup ecosystem constantly evolves, the question on everyone's mind is: When will the startup funding winter thaw? In September, we witnessed five Indian startups securing substantial investments, each exceeding $100 million. While these funding events bring optimism, they also make us wonder if things are getting better for tech and digital startups.

Share Market Live

NSE

To gain deeper insights into the current state of the Indian startup funding scenario, CNBC-TV18's Nisha Poddar spoke to Arpit Agarwal, Investment Partner at Blume Ventures. Agarwal highlighted that while the startup funding winter persists, there are discernible trends within the market. Late-stage deals continue to be sluggish, with many companies taking longer to secure funding, often at valuations lower than expected.

However, Agarwal noted a positive shift in investor preferences. He emphasised that investors are increasingly favoring companies with positive EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) and PAT (Profit After Tax) figures.

He added, “What is definitely happening in the market is that there is a very strong preference towards EBITDA and PAT-positive companies. So, the late stage deals which are actually happening in the Indian market are largely close to EBITDA or close to PAT positive company which is a good positive sign. There is a clear preference in the market at this point of time.”

Read Here | Angel One acquires fintech startup DStreet Finance to tap GenZ

While there are signs of change, Agarwal remained cautious about predicting an imminent revival in the startup funding environment.

“As far as revival is concerned I am suspecting that we may not have any revival in sight till maybe June of next year. That is the guidance we have given to our portfolio companies that they should not expect any more funding infusion internal and external till then. If something happens, of course, we should take it but not count on it and therefore cash conservation is the key theme at this point of time.”

JSW Ventures, a prominent player in the Indian startup investment scene, made headlines with two significant deals this week. They invested in Growcoms, a company specialising in spices, and also announced a stake sale in Purplle, a beauty omni-channel player.

For full interview, watch accompanying video

(Edited by : Asmita Pant)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Neurocrine Biosciences Says Ingrezza Shows Earlier Remission of Tardive Dyskinesia Symptoms
Neurocrine Biosciences Says Ingrezza Shows Earlier Remission of Tardive Dyskinesia Symptoms
Sep 23, 2025
09:29 AM EDT, 09/23/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Tuesday that a phase 4 open-label study confirmed robust rates of symptomatic remission of tardive dyskinesia with once-daily Ingrezza capsules. The analysis also showed sustained improvements in patient-reported outcomes among participants who achieved symptomatic remission, the company said. Shares of the company were down 1% in recent...
Solid Biosciences Signs Licensing Deal With Kinea Bio for AAV-SLB101 to Treat Muscular Dystrophy
Solid Biosciences Signs Licensing Deal With Kinea Bio for AAV-SLB101 to Treat Muscular Dystrophy
Sep 23, 2025
08:31 AM EDT, 09/23/2025 (MT Newswires) -- Solid Biosciences ( SLDB ) said Tuesday that it has signed a non-exclusive licensing and collaboration agreement with Kinea Bio to use Solid Biosciences' ( SLDB ) proprietary AAV-SLB101 to treat muscle tropism and reduced liver uptake. Under the terms of the deal, Solid has granted Kinea Bio a non-exclusive worldwide license to...
Midland Exploration Starts Follow Up Program On Its New Discovery Of Gold-Zinc-Silver Mineralization at Caniapisc Au Project
Midland Exploration Starts Follow Up Program On Its New Discovery Of Gold-Zinc-Silver Mineralization at Caniapisc Au Project
Sep 23, 2025
09:29 AM EDT, 09/23/2025 (MT Newswires) -- Midland Exploration ( MIDLF ) announced Tuesday the start of a follow-up exploration program on its new discovery of gold, zinc, and silver on its Caniapisc Au project, in the Eeyou Istchee James Bay and Caniapiscau regions, and also announced map designation of two new projects in the same area. A statement noted...
Connexi Expands Global Supply Chain Capabilities with Acquisition of Crown Agents Inspections Private Limited
Connexi Expands Global Supply Chain Capabilities with Acquisition of Crown Agents Inspections Private Limited
Sep 23, 2025
WASHINGTON and NEW DELHI, Sept. 23, 2025 /PRNewswire/ -- Connexi, Chemonics International's supply chain subsidiary, today announced the acquisition of Crown Agents Inspections Private Limited, or CA Inspections, a leading quality assurance and inspection services provider in India. The acquisition strengthens Connexi's ability to deliver end-to-end supply chain solutions, expanding its reach in Asia and enhancing its capacity for product...
Copyright 2023-2026 - www.financetom.com All Rights Reserved